ironXS: High-school screening for hereditary haemochromatosis is acceptable and feasible

European Journal of Human Genetics

Volumn 20, Issue 5, 2012, Pages 505-509

  Delatycki, Martin B ^a,b,c   Wolthuizen, Michelle ^a   Collins, Veronica ^a   Varley, Elizabeth ^a   Craven, Joanna ^a   Allen, Katrina J ^a,b,d   Gurrin, Lyle C ^b   Aitken, Maryanne ^a,b   Trembath, M Kaye ^a   Bond, Lyndal ^e   Wilson, Gabrielle R ^a   Stephenson, Sarah E M ^a,b   Macciocca, Ivan ^f   Hickerton, Chriselle ^a   Lockhart, Paul J ^a,b   Metcalfe, Sylvia A ^a,b  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e MRC SOCIAL AND PUBLIC HEALTH SCIENCES UNIT   (United Kingdom)

^f Genetic Health Services Victoria   (Australia)

Author keywords

adolescent health; genetic screening; haemochromatosis; high school; informed consent

Indexed keywords

ADOLESCENT; ADULT; AFFECT; ANXIETY; ARTICLE; FEASIBILITY STUDY; FEMALE; GENETIC SCREENING; HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; HIGH RISK PATIENT; HIGH SCHOOL STUDENT; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PERCEPTION; POSITIVE AND NEGATIVE AFFECT SCHEDULE NEGATIVE; POSITIVE AND NEGATIVE AFFECT SCHEDULE POSITIVE; PRIORITY JOURNAL; SHORT FORM 36; STATE TRAIT ANXIETY INVENTORY;

ADOLESCENT; FEASIBILITY STUDIES; GENETIC TESTING; GENOTYPE; HEMOCHROMATOSIS; HUMANS; MEMBRANE PROTEINS; QUESTIONNAIRES;

EID: 84859913341     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2011.247     Document Type: Article

References (35)

1. Calzone K, Wattendorf D, Dunn BK: The application of genetics and genomics to cancer prevention. Semin Oncol 2010; 37: 407-418.
2. Humphries SE, Drenos F, Ken-Dror G, Talmud PJ: Coronary heart disease risk prediction in the era of genome-wide association studies: current status and what the future holds. Circulation 2010; 121: 2235-2248.
3. Delatycki MB: Population screening for reproductive risk for single gene disorders in Australia: now and the future. Twin Res Hum Genet 2008; 11: 422-430.
4. Allen KJ, Gurrin LC, Constantine CC et al: Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-230.
5. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T: Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-218. (Pubitemid 34113819)
6. Allen KJ, Warner B, Delatycki MB: Clinical haemochromatosis in HFE mutation carriers. Lancet 2002; 360: 412-413,
7. Cox T, Rochette J, Camaschella C, Walker A, Robson K: Clinical haemochromatosis in HFE mutation carriers. Lancet 2002; 360: 412.
8. Poullis A, Moodie SJ, Maxwell JD: Clinical haemochromatosis in HFE mutation carriers. Lancet 2002; 360: 411-412.
9. Patch C, Roderick P, Rosenberg W: Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and phenotypic strategy for screening for haemochromatosis. J Hepatol 2005; 43: 149-155. (Pubitemid 40805286)
10. Delatycki MB, Allen KJ, Nisselle AE et al: Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005; 366: 314-316. (Pubitemid 41019421)
11. Cadet E, Capron D, Gallet M et al: Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases. J Med Genet 2005; 42: 390-395. (Pubitemid 40685679)
12. Gason AA, Aitken MA, Metcalfe SA, Allen KJ, Delatycki MB: Genetic susceptibility screening in schools: attitudes of the school community towards hereditary haemochromatosis. Clin Genet 2005; 67: 166-174. (Pubitemid 40287524)
13. Gason A, Sheffield E, Bankier A et al: Evaluation of a Tay-Sachs disease screening program. Clin Genet 2003; 63: 386-392. (Pubitemid 36966021)
14. Mitchell JJ, Capua A, Clow C, Scriver CR: Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet 1996; 59: 793-798. (Pubitemid 26328074)
15. Metcalfe SA, Aitken M, Gaff CL: The importance of program evaluation: how can it be applied to diverse genetics education settings? J Genet Couns 2008; 17: 170-179.
16. Delatycki MB, Wolthuizen M, Collins V et al: Implementation of ironXS: a study of the acceptability and feasibility of genetic screening for hereditary hemochromatosis in high schools. Clin Genet 2010; 77: 241-248.
17. Delatycki M, Allen K, Williamson R: Insurance agreement to facilitate genetic testing. Lancet 2002; 359: 1433. (Pubitemid 34442391)
18. Ware Jr JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
19. Marteau TM, Bekker H: The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992; 31: 301-306.
20. Spielberger C, Gorusch R, Luchene R: State-Trait Anxiety Inventory: Manual. Consulting Psychologists Press: Palo Alto, 1983.
21. Melvin GA, Molloy GN: Some psychometric properties of the Positive and Negative Affect Schedule among Australian youth. Psychol Rep 2000; 86: 1209-1212.
22. Watson D, Clark LA, Tellegen A: Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988; 54: 1063-1070.
23. Horowitz M, Wilner N, Alvarez W: Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979; 41: 209-218. (Pubitemid 9219271)
24. Gason AA, Metcalfe SA, Delatycki MB et al: Tay Sachs disease carrier screening in schools: educational alternatives and cheekbrush sampling. Genet Med 2005; 7: 626-632. (Pubitemid 41753014)
25. Schmitt B, Golub RM, Green R: Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005; 143: 522-536.
26. Power TE, Adams PC, Barton JC et al: Psychosocial impact of genetic testing for hemochromatosis in the HEIRS Study: a comparison of participants recruited in Canada and in the United States. Genet Test 2007; 11: 55-64. (Pubitemid 46557358)
27. Wenzel LB, Anderson R, Tucker DC et al: Health-related quality of life in a racially diverse population screened for hemochromatosis: results from the Hemochromatosis and Iron Overload Screening (HEIRS) study. Genet Med 2007; 9: 705-712. (Pubitemid 350287156)
28. Patch C, Roderick P, Rosenberg W: Comparison of genotypic and phenotypic strategies for population screening in hemochromatosis: assessment of anxiety, depression, and perception of health. Genet Med 2005; 7: 550-556. (Pubitemid 41566481)
29. Power TE, Adams PC: Psychosocial impact of C282Y mutation testing for hemochromatosis. Genet Test 2001; 5: 107-110. (Pubitemid 32801826)
30. Nisselle AE, Collins VR, Gason AA et al: Educational outcomes of a workplace screening program for genetic susceptibility to hemochromatosis. Clin Genet 2006; 69: 163-170. (Pubitemid 43372281)
31. Frumkin A, Zlotogora J: Genetic screening for reproductive purposes at school: is it a good strategy? Am J Med Genet A 2008; 146A: 264-269.
32. Allen K, Williamson R: Screening for hereditary haemochromatosis should be implemented now. BMJ 2000; 320: 183-184. (Pubitemid 30179374)
33. Haddow JE, Bradley LA: Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled. BMJ 1999; 319: 531-532. (Pubitemid 29403630)
34. Hall MA, Barton JC, Adams PC et al: Genetic screening for iron overload: No evidence of discrimination at 1 year. J Fam Pract 2007; 56: 829-834. (Pubitemid 350072156)
35. Smith CO, Lipe HP, Bird TD: Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders. Arch Neurol 2004; 61: 875-880. (Pubitemid 38747326)